Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008
Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004
Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003
Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006
Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002
Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016
Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006
The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002
The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Influence of inhaled nitric oxide on plasma endothelin-1 in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003
Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction Source: Eur Respir J 2003; 21: 19-24 Year: 2003
Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Upregulation of endothelial nitric oxide synthase in pulmonary artery of infants with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 694s Year: 2004
Nitric oxide metabolite flux during exercise in pulmonary arterial hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011
Physical training and metabolics of nitric oxide in individuals with idiopathic pulmonary arterial hypertension. Source: International Congress 2019 – Exercise tolerance and its determinants across pathologies Year: 2019